Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) Peptid
Kurzübersicht für Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) Peptid (ABIN8103619)
Target
Quelle
Applikation
-
-
Verwendungszweck
- KLKB1 Peptide
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
This is a synthetic peptide designed for use in combination with anti-KLKB1 antibody ( ARP45678_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Buffer
- Lyophilized powder
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
-
-
- KLKB1 (Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1))
-
Hintergrund
-
Background Information: Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. Plasma prekallikrein is converted to plasma kallikrein by factor XIIa by the cleavage of an internal Arg-Ile bond. Plasma prekallikrein deficiency causes a prolonged activated partial thromboplastin time in patients.Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. Plasma prekallikrein is converted to plasma kallikrein by factor XIIa by the cleavage of an internal Arg-Ile bond. Plasma kallikrein therefore is composed of a heavy chain and a light chain held together by a disulphide bond. The heavy chain originates from the amino-terminal end of the zymogen and contains 4 tandem repeats of 90 or 91 amino acids. Each repeat harbors a novel structure called the apple domain. The heavy chain is required for the surface-dependent pro-coagulant activity of plasma kallikrein. The light chain contains the active site or catalytic domain of the enzyme and is homologous to the trypsin family of serine proteases. Plasma prekallikrein deficiency causes a prolonged activated partial thromboplastin time in patients.
Alternative Symbols: KLK3, PPK
-
Molekulargewicht
- 28kDa
-
Gen-ID
- 3818
-
NCBI Accession
- NP_000883
-
UniProt
- P03952
Target
-